Headlines

US BROKER MOVES: PANW double upgraded at Arete; SABR downgraded at Bernstein

Newsquawk Staff ·

UPGRADES

  • 1stdibs (DIBS) upgraded from Market Perform to Outperform at Northland
  • Innovative Industrial Properties (IIPR) upgraded from Sell to Neutral at Compass Point; PT USD 45
  • Palo Alto Networks (PANW) upgraded from Sell to Buy at Arete; PT USD 185
  • Unity Software (U) upgraded from Underperform to Neutral at BofA Securities; PT USD 19 (prev. USD 18)
  • Block (XYZ) upgraded from Hold to Buy at HSBC; PT USD 77 (prev. USD 70)

DOWNGRADES

  • AES Corp (AES) downgraded from Outperform to Neutral at Mizuho; PT USD 15 (prev. USD 16)
  • DHT Holdings (DHT) downgraded from Buy to Hold at DNB Carnegie
  • Mosaic (MOS) downgraded from Overweight to Equalweight at Barclays; PT USD 31
  • uniQure (QURE) downgraded from Outperform to Neutral at Mizuho; PT USD 12 (prev. USD 33)
  • uniQure (QURE) downgraded from Overweight to Equal Weight at Wells Fargo; PT USD 15 (prev. USD 60)
  • Sabre (SABR) downgraded from Outperform to Market Perform at Bernstein SocGen; PT USD 1.50
  • Select Medical (SEM) downgraded from Outperform to Sector Perform at RBC Capital; PT USD 16.50 (prev. USD 19.00)
  • BlackRock TCP Capital (TCPC) downgraded from Market Perform to Underperform at KBW; PT USD 3.50 (prev. USD 7.00)
  • Grupo Televisa (TV) downgraded from Overweight to Neutral at JPMorgan

INITIATIONS

  • Agios Pharmaceuticals (AGMB) initiated at Outperform at Leerink Partners; PT USD 36
  • Agios Pharmaceuticals (AGMB) initiated at Overweight at Morgan Stanley; PT USD 28
  • Agios Pharmaceuticals (AGMB) initiated at Overweight at JPMorgan; PT USD 32
  • Amylyx Pharmaceuticals (AMLX) initiated at Buy at Stifel; PT USD 21
  • Carpenter Technology (CRS) initiated at Positive at Susquehanna; PT USD 470
  • Healthcare Services Group (HCSG) initiated at Sector Perform at RBC Capital; PT USD 22
  • IQVIA (IQV) initiated at Outperform at RBC Capital; PT USD 221
  • Luckin Coffee (LKNCY) initiated at Add at China Galaxy International; PT USD 52
  • Medpace (MEDP) initiated at Outperform at RBC Capital; PT USD 522
  • Oportun Financial (OFRM) initiated at Buy at BofA Securities; PT USD 26
  • Oportun Financial (OFRM) initiated at Buy at Goldman Sachs; PT USD 43
  • Oportun Financial (OFRM) initiated at Equalweight at Barclays; PT USD 25
  • Oportun Financial (OFRM) initiated at Hold at Deutsche Bank; PT USD 25
  • Oportun Financial (OFRM) initiated at Hold at TD Cowen; PT USD 26
  • Oportun Financial (OFRM) initiated at In Line at Evercore ISI; PT USD 26
  • Oportun Financial (OFRM) initiated at Outperform at Oppenheimer
  • Oportun Financial (OFRM) initiated at Outperform at William Blair
  • Oportun Financial (OFRM) initiated at Overweight at JPMorgan; PT USD 29
  • Ormat Technologies (ORA) initiated at Outperform at RBC Capital; PT USD 130
  • Sagimet Biosciences (SGP) initiated at Buy at Citi; PT USD 42
  • Sagimet Biosciences (SGP) initiated at Buy at Stifel; PT USD 42
  • Sagimet Biosciences (SGP) initiated at Buy at Jefferies; PT USD 62
  • Sagimet Biosciences (SGP) initiated at Outperform at Leerink Partners; PT USD 42

What it means

The upgrades and downgrades in analyst ratings indicate a significant shift in sentiment towards specific stocks. Notably, Palo Alto Networks (PANW) was double upgraded from Sell to Buy, reflecting a confident outlook and potentially driving positive price movement, while Sabre (SABR) being downgraded from Outperform to Market Perform suggests reduced expectations, which may weigh on its stock performance. The implications for these ratings can affect sector sentiment and should be monitored closely as they may influence trading strategies.

Related headlines